JP3051413B2 - Substances that cross the blood-brain barrier - Google Patents
Substances that cross the blood-brain barrierInfo
- Publication number
- JP3051413B2 JP3051413B2 JP1186086A JP18608689A JP3051413B2 JP 3051413 B2 JP3051413 B2 JP 3051413B2 JP 1186086 A JP1186086 A JP 1186086A JP 18608689 A JP18608689 A JP 18608689A JP 3051413 B2 JP3051413 B2 JP 3051413B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acids
- blood
- brain
- sugar
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 title claims description 31
- 230000008499 blood brain barrier function Effects 0.000 title claims description 9
- 210000001218 blood-brain barrier Anatomy 0.000 title claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 150000008163 sugars Chemical class 0.000 claims description 15
- 210000004556 brain Anatomy 0.000 claims description 14
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 12
- 235000013734 beta-carotene Nutrition 0.000 claims description 12
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 12
- 239000011648 beta-carotene Substances 0.000 claims description 12
- 229960002747 betacarotene Drugs 0.000 claims description 12
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 12
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 201000004384 Alopecia Diseases 0.000 claims description 7
- -1 dursit Chemical compound 0.000 claims description 7
- 230000003676 hair loss Effects 0.000 claims description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 235000008210 xanthophylls Nutrition 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000009697 arginine Nutrition 0.000 claims description 4
- 230000037406 food intake Effects 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 229960005375 lutein Drugs 0.000 claims description 4
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 4
- 239000002858 neurotransmitter agent Substances 0.000 claims description 4
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- AYRXSINWFIIFAE-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-AGQMPKSLSA-N D-lyxopyranose Chemical compound O[C@@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-AGQMPKSLSA-N 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-VAYJURFESA-N aldehydo-L-arabinose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VAYJURFESA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-KCDKBNATSA-N aldehydo-L-fucose Chemical compound C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-KCDKBNATSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-YUPRTTJUSA-N aldehydo-L-lyxose Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-YUPRTTJUSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-MBMOQRBOSA-N alpha-D-arabinopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@@H]1O SRBFZHDQGSBBOR-MBMOQRBOSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 235000004554 glutamine Nutrition 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000007659 motor function Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102220240796 rs553605556 Human genes 0.000 description 6
- 230000003779 hair growth Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 150000002337 glycosamines Chemical class 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 3
- 235000015205 orange juice Nutrition 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 産業上の利用分野 本発明は他の物質を血液脳関門の中に通す及び輸送す
る物質及び方法に関する。本発明は、特にアルコール中
毒の作用を克服する及び禿頭症を克服する物質及び方法
に関する。Description: FIELD OF THE INVENTION The present invention relates to materials and methods for passing and transporting other materials through the blood-brain barrier. The invention relates in particular to substances and methods for overcoming the effects of alcoholism and overcoming baldness.
従来の技術 ほとんどの生理的機能が脳によって制御されており、
その制御の媒体は脳内の化学的活性へのインシデントと
しての電気的信号法であるという前提を認めるならば、
その活性に必要とされる化学物質が脳内に無くなれば信
号不全、及びその結果、生理的無機能に至り得ると結論
することは論理にかなっていると思われる。また、所定
の物質が脳内に存在すれば制御信号の適当な発生を化学
的に妨げ得ると結論することが可能である。Conventional technology Most physiological functions are controlled by the brain,
Given the premise that the medium of control is electrical signaling as an incident to chemical activity in the brain,
It seems logical to conclude that the absence of chemicals required for its activity in the brain could lead to signal failure and, consequently, physiological disfunction. It can also be concluded that the presence of certain substances in the brain can chemically prevent proper generation of control signals.
このような考察、薬剤従属症、酩酊、禿頭症及びその
他の疾病、脳に関連するいくつかの病気、等の機構を理
解する調査は多くの研究者が脳内のこのような疾病と化
学物質の利用性との間の関係をさがすのを明らかに拒否
してきた。医学文献に、所定の病気で死んだ人の脳組織
を関係のない原因で死んだ人の脳組織と比べて所定の化
学物質と病気との間に関係があることを提案する記述が
載っている。これによれば、リチウムの欠乏が精神分裂
病に関係すると述べられ、神経ペプチドの欠乏がアルツ
ハイメル病に関係すると述べられてきた。Research that understands the mechanisms of such considerations, drug addiction, drunkenness, baldness and other illnesses, some brain-related illnesses, etc. has shown that many researchers have identified such diseases and chemicals in the brain. He has clearly refused to look for a relationship between usability and the utility. The medical literature contains a statement that suggests that there is a relationship between certain chemicals and disease compared to brain tissue of a person who died of a certain disease compared to brain tissue of a person who died of unrelated causes. I have. It states that lithium deficiency is associated with schizophrenia and neuropeptide deficiency is associated with Alzheimer's disease.
その領域における研究、脳癌の化学的治療及びその他
の研究及び手順は、一般に血液脳関門とよばれているも
ののために化学物質を脳に導入する際の困難性によって
妨げられる。脳の血管は体のどこか他の血管に比べて一
層最密な細胞で形成されている。そのこと及び星状細胞
の作用は、多くの物質が脳の神経膠に導入し難いことの
原因となる。いくつかの場合では、研究者がそれらの物
質を至らせる唯一の方法は被検者の頭骨に孔を形成して
所望の物質を脳の中に注入することであった。Research in that area, chemotherapy for brain cancer, and other research and procedures are hampered by difficulties in introducing chemicals into the brain because of what is commonly called the blood-brain barrier. Blood vessels in the brain are formed of denser cells than any other blood vessel in the body. That and the action of the astrocytes causes many substances to be difficult to introduce into the glia of the brain. In some cases, the only way for researchers to reach those substances was to form a hole in the subject's skull and inject the desired substance into the brain.
発明の目的は血液脳関門を通して物質を輸送するビヒ
クル及び方法を提供するにある。It is an object of the invention to provide vehicles and methods for transporting substances across the blood-brain barrier.
別の目的は特定の疾病の研究及びいくつかの場合には
治療に適した特定の物質を提供することにある。それら
の疾病の内の一つは毛髪の損失であり、別のものは酩酊
へのインシデントとしての運動機能の損失である。Another object is to provide certain substances that are suitable for studying and in some cases treating certain diseases. One of those diseases is loss of hair and another is loss of motor function as an incident to drunkenness.
発明の構成 本明細書中以降で明らかになるものと思う発明のこれ
らや他の目的及び利点は、通常血液脳関門を通過するこ
とができない物質の血液から脳への迅速な通過を促進す
る物質及びこのような物質と、例えば妨げられる神経伝
達物質(ニューロトランスミッター)の機能を回復し及
び毛髪生長の回復を促進することができる他の物質との
組合せを提供することによって達成される。他の物質を
関門の中に通して輸送することに関して責任のある物質
は多数の微粉状の極めて純粋な濃厚な糖或はアミノ糖の
内のいずれか一つの単独或はこれらの組合わせである。
糖は下記である:メソエリトリトール、キシリトール、
D(+)ガラクトース、D(+)ラクトース、D(+)
キシロース、ズルシット、ミオイノシトール、L(−)
フルクトース、D(−)マンニトール、ソルビトール、
D(+)グルコース、D(+)アラビノース、D(−)
アラビノース、セロビオース、D(+)マルトース、D
(+)ラフィノース、L(+)ラムノース、D(+)メ
リビオース、D(−)リボース、アドニット、D(+)
アラビトール、L(−)アラビトール、D(+)フコー
ス、L(−)フコース、D(−)リキソース、L(+)
リキソース、L(−)リキソース、D(+)グルコサミ
ン、Dマンノサミン及びDガラクトサミン。本明細書
中、糖に適用する通りの「純」なる用語は結晶純度97〜
99%の純度を意味する。高純度を要件とすることは、純
度を必要とすること及び不純物の性質がわかっておら
ず、いくつかの不純物は糖或はアミノ酸の有効性を無効
にすることの両方に基づく。微粉化を要件とすること
は、主に迅速な作用を望むことに基づく。SUMMARY OF THE INVENTION These and other objects and advantages of the invention, which will become apparent hereinafter, are materials that facilitate the rapid passage of blood-to-brain materials that cannot normally pass through the blood-brain barrier. It is achieved by providing a combination of such substances with other substances that can, for example, restore the function of blocked neurotransmitters (neurotransmitters) and promote the restoration of hair growth. The substance responsible for transporting other substances through the barrier is any one or a combination of any one of a number of finely divided, highly pure, concentrated sugars or amino sugars. .
The sugars are: mesoerythritol, xylitol,
D (+) galactose, D (+) lactose, D (+)
Xylose, dursit, myo-inositol, L (-)
Fructose, D (-) mannitol, sorbitol,
D (+) glucose, D (+) arabinose, D (-)
Arabinose, cellobiose, D (+) maltose, D
(+) Raffinose, L (+) rhamnose, D (+) melibiose, D (-) ribose, adunit, D (+)
Arabitol, L (-) arabitol, D (+) fucose, L (-) fucose, D (-) lyxose, L (+)
Lyxose, L (-) lyxose, D (+) glucosamine, D mannosamine and D galactosamine. As used herein, the term "pure" as applied to sugars has a crystal purity of 97-90.
Means 99% purity. The requirement for high purity is based both on the need for purity and the unknown nature of the impurities, some of which impair the effectiveness of sugars or amino acids. The requirement for micronization is mainly based on the desire for rapid action.
酩酊被検者の運動機能を迅速に回復することを目的と
する場合、糖を下記のリストから採用するある分量の1
種或はそれ以上のアミノ酸と組合わせる。アミノ酸は下
記である:グルタミン、リシン、アルギニン、アスパラ
ギン、アスパラギン酸、システイン、グルタミン酸、グ
リシン、ヒスチジン、ロイシン、メチオニン、フェニル
アラニン、プロリン、セリン、トレオニン、トリプトフ
ァン、チロシン、バリン及びタウリン。アミノ酸は普通
の食品、例えばオレンジジュース、クラムチャウダー、
大豆スープ、羊乳、等の中に見出されるものにすること
ができるが、結果を均一にしかつ一層予測可能にするた
めに、アミノ酸を純結晶の形で加入するのが好ましい。For the purpose of quickly restoring the motor function of a drunken subject, a certain amount of sugar is used from the list below.
Combined with species or more amino acids. The amino acids are: glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and taurine. Amino acids are common foods, such as orange juice, clam chowder,
Although it can be found in soy soups, sheep's milk, and the like, it is preferred to add the amino acids in the form of pure crystals to make the results uniform and more predictable.
体の中のエーテルが過剰になる結果として運動機能の
調節を失った者に運動機能を迅速に回復させるのが目的
の場合、アミノ酸が必須成分である。他の物質を血液脳
関門を通して脳に導入することを目的とする場合、アミ
ノ酸は望ましいが、明らかに必須成分ではない。これよ
り、例えばある分量の1種或はそれ以上の上述した糖を
ベータカロチン或はキサントフィルと共に摂取すれば毛
髪の生長を促進するが、その生長プロセスは、上記から
のアミノ酸を加える場合に促進される。Amino acids are an essential component if the goal is to quickly restore motor function to those who have lost control of motor function as a result of excess ether in the body. For the purpose of introducing other substances into the brain through the blood-brain barrier, amino acids are desirable but obviously not essential. Thus, for example, ingestion of a quantity of one or more of the above sugars with beta-carotene or xanthophyll promotes hair growth, but the growth process is accelerated when amino acids from above are added. You.
添加する試験或は治療用物質のそれらの物質を組合わ
せる割合及びその組合せの量は共に試験用被検者の性質
及び重量によって変わる。ヒトの場合、上記した糖のい
ずれかの過度の量ははき気、発熱感覚、潮紅及び耳鳴り
を引き起こし得る。一度に投与する糖を5グラムより多
くすれば上述した悪い副作用を生じ得る。アミノ酸の量
を過剰にすれば所定の病気にかかった被検者に対し有害
な作用を与える他は、安全に摂取するアミノ酸の量に上
限はない。Both the proportions of the test or therapeutic substances added and their combination in combination and the amount of the combination will depend on the nature and weight of the test subject. In humans, excessive amounts of any of the above sugars can cause nausea, fever sensation, flushing and tinnitus. If more than 5 grams of sugar is administered at one time, the adverse side effects described above can occur. There is no upper limit on the amount of amino acids that can be safely taken, except that excessive amounts of amino acids may have a detrimental effect on a subject with a given disease.
好ましい実施態様の説明 アミノ酸の包含はアルコールの作用を克服し及び運動
機能の迅速な回復を達成する他は必須でないが、他の物
質を脳に輸送するのに有用であり、それで、好ましい実
施態様では加入する。これより、発明の好ましい物質は
血液脳関門を通りかつ他の物質を関門を通して輸送する
能力を有するものであり、多数の純糖或は純アミノ糖の
内の1種或はそれ以上と多数のアミノ酸の内の1種或は
それ以上との組合せを含む。糖は下記の通りである:メ
ソエリトリトール、チリトール、D(+)ガラクトー
ス、D(+)ラクトース、D(+)キシロース、ズルシ
ット、ミオイノシトール、L(−)フルクトース、D
(−)マンニトール、ソルビトール、D(+)グルコー
ス、D(+)アラビノース、D(−)アラビノース、セ
ロビオース、D(+)マルトース、D(+)ラフィノー
ス、L(+)ラムノース、D(+)メリビオース、D
(−)リボース、アドニット、D(+)アラビトール、
L(−)アラビトール、D(+)フコース、L(−)フ
コース、D(−)リキソース、L(+)リキソース及び
L(−)リキソース。本明細書中、糖に適用する通りの
「純」なる用語は結晶純度97〜100%純度の微粉糖を意
味する。アミノ糖はD(+)グルコサミン、Dマンノサ
ミン及びDガラクトサミンである。本明細書中以降で、
アミノ糖は「糖」なる用語に含まれる。DESCRIPTION OF THE PREFERRED EMBODIMENTS Inclusion of amino acids is not essential except that it overcomes the effects of alcohol and achieves rapid recovery of motor function, but is useful for transporting other substances to the brain, and is therefore a preferred embodiment. Then join. Thus, preferred substances of the invention are those that have the ability to cross the blood-brain barrier and transport other substances through the barrier, and may comprise one or more of a number of pure sugars or amino sugars and a number of pure sugars. Includes combinations with one or more of the amino acids. The sugars are as follows: mesoerythritol, chylitol, D (+) galactose, D (+) lactose, D (+) xylose, dursit, myo-inositol, L (-) fructose, D
(-) Mannitol, sorbitol, D (+) glucose, D (+) arabinose, D (-) arabinose, cellobiose, D (+) maltose, D (+) raffinose, L (+) rhamnose, D (+) melibiose , D
(-) Ribose, adunit, D (+) arabitol,
L (-) arabitol, D (+) fucose, L (-) fucose, D (-) lyxose, L (+) lyxose and L (-) lyxose. As used herein, the term "pure" as applied to sugars refers to pulverized sugars having a purity of 97-100% crystalline. Amino sugars are D (+) glucosamine, D mannosamine and D galactosamine. From here onwards,
Amino sugars are included in the term "sugar".
アミノ酸は下記である:グルタミン、リシン、アルギ
ニン、アスパラギン、アスパラギン酸、システイン、グ
ルタミン酸、グリシン、ヒスチジン、ロイシン、メチオ
ニン、フェニルアラニン、プロリン、セリン、トレオニ
ン、トリプトファン、チロシン、バリン及びタウリン。
アルギニン、トリプトファン、チロシンが現時点で好ま
しい。発明の物質を、例えば、水或はオレンジジュース
等の液体で経口摂取するのがずっと好ましい。The amino acids are: glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and taurine.
Arginine, tryptophan, tyrosine are presently preferred. It is even more preferred that the substance of the invention is taken orally, for example, in a liquid such as water or orange juice.
酩酊作用の克服 酩酊作用の克服を目的とする場合に、上述した組成物
が好ましい。迅速に作用するための物質の最少有効量は
被検者の体重に依存する。100ポンド(45kg)の個体の
場合、高純度糖の最少量は約1.2グラムであり、アミノ
酸の最少量は約400ミリグラムである。200ポンド(91k
g)の個体の場合、最少量は高純度糖約2.0〜2.5グラム
であり、アミノ酸約480ミリグラムである。一方は運動
機能を回復するためであり、他方はアルコールを代謝す
るためである。運動機能を迅速に回復するには高純度糖
を要する。アルコールの適度に迅速な代謝を促進するた
めには、糖の純度を90%又はそれ以上にすることを要す
るだけである。最少量の「純」糖を入れる場合、糖の混
合物も許される。高純度糖とアミノ酸との組合せは、液
状で或は液体で摂取する場合、経口摂取した後、1分よ
り短い時間で、通常30秒以内で運動機能を回復するに至
る。80プルーフアルコールを6オンス(17グラム)摂取
しておりかつ発明の物質を液体の形で経口摂取する通常
の200ポンドの個体における血中アルコールの量を30分
以内で0.05%より低く低減させる。比較的迅速な解毒は
一部アミノ酸を含むことによる。Overcoming drunkenness The above-described compositions are preferred for the purpose of overcoming drunkenness. The minimum effective amount of a fast acting substance will depend on the subject's weight. For a 100 pound (45 kg) individual, the minimum amount of high purity sugar is about 1.2 grams and the minimum amount of amino acids is about 400 milligrams. 200 pounds (91k
For g) individuals, the minimum amount is about 2.0-2.5 grams of high purity sugar and about 480 milligrams of amino acids. One is to restore motor function and the other is to metabolize alcohol. Rapid recovery of motor function requires high purity sugar. To promote the reasonably rapid metabolism of alcohols only requires a sugar purity of 90% or higher. If a minimal amount of "pure" sugar is included, a mixture of sugars is also permitted. The combination of high-purity sugars and amino acids, when taken in liquid or liquid form, restores motor function in less than 1 minute, usually within 30 seconds after oral ingestion. Reduces the amount of blood alcohol in a normal 200 lb. individual consuming 6 ounces (17 grams) of 80 proof alcohol and orally ingesting the substance of the invention in liquid form to less than 0.05% within 30 minutes. Relatively rapid detoxification is due to the inclusion of some amino acids.
毛髪生長 所定の物質は毛髪の損失を遅らせるのに有用であるこ
とが立証された。毛髪の損失を減少させかつ毛髪を回復
させる両方である程度良好な結果が得られると称する有
標製品は多数市販されている。それらは外部適用し、毛
髪胞細胞の表面でニューロリセプターとして働くものと
考えられている。発明の物質はベータカロチン及び/又
はキサントフィルであり、これは神経膠に導入した際に
手包に信号を発して作用させる神経伝達物質として働く
ことができる。試験は、ベータカロチン及び/又はキサ
ントフィルを上述した1種或はそれ以上の高純度糖と共
に摂取する場合に、毛髪生長を促進することを立証す
る。頭の領域における毛髪生長は前にはげていた。1つ
の試験では、ベータカロチン30mgをオレンジジュース25
0cc中のフルクトース2500mgと共に毎日45日間摂取した
ところ、使用者の毛の生え際における毛髪損失を停止し
かつ頂の領域において新しい毛髪が生長するに至った。
自然の毛髪色が黒色であり、グレーに変った被検者は、
45日の試験の終りに事実上黒色だけの頭蓋毛及び体毛を
有していた。Hair Growth Certain substances have proven to be useful in delaying hair loss. There are a number of proprietary products on the market that claim to provide some good results both in reducing hair loss and in restoring hair. They are applied externally and are thought to act as neuroreceptors on the surface of hair follicle cells. The substances of the invention are beta-carotene and / or xanthophylls, which can act as neurotransmitters that, when introduced into the glia, signal and act on the sac. The tests demonstrate that beta carotene and / or xanthophyll promote hair growth when taken with one or more of the high purity sugars described above. Hair growth in the area of the head was previously bald. In one study, beta-carotene 30 mg was added to orange juice 25.
Ingestion daily with 2500 mg of fructose in 0 cc for 45 days stopped the hair loss at the user's hairline and led to the growth of new hair in the area of the top.
A subject whose natural hair color is black and turned gray,
At the end of the 45-day test, he had virtually only black skull and hair.
試験は、ベース物質、糖、アミノ酸が上述した量で、
ベータカロチン及びその他の物質を約半時間で輸送する
に至るのに有効であることを示す。それが、糖がその期
間血液中に残るためであるか或はその期間継続する脳内
の作用を生じるためであるかどうかはわかっていない。
しかし、ベータカロチンは、その作用のために、ベース
物質と共に摂取する必要はなく、結局取り出される点に
おいて摂取することができる。ベータカロチンの臨界投
与量はないように思われる。ベータカロチンは摂取する
ことから、かつその推奨される毎日の量は5000IUである
ことから、現時点で、その量が好ましい最少であると考
えられる。ベータカロチンの量を50,000IUより多くして
も毛髪回復の促進は観察されなかった。そのため、現時
点で、50,000IUがそれ以上増大させても費用を増大する
だけで利点をそれ以上生じない上限であると考えられ
る。ベータカロチン及びキサントフィルは同等に有効で
ある。The test is based on the amounts of base substance, sugar and amino acid described above,
It shows that beta carotene and other substances are effective to transport in about half an hour. It is not known whether it is due to the sugar remaining in the blood for that period or to producing effects in the brain that last for that period.
However, beta-carotene does not need to be taken with the base substance for its action, but can be taken at the point where it is eventually removed. There appears to be no critical dose of beta-carotene. Beta-carotene is considered to be the preferred minimum at this time, since it is consumed and its recommended daily amount is 5000 IU. No increase in hair recovery was observed with beta-carotene levels greater than 50,000 IU. Therefore, at this time, 50,000 IU is considered to be the upper limit at which increasing it further does not produce any additional benefit at the expense of additional cost. Beta-carotene and xanthophyll are equally effective.
フロントページの続き (51)Int.Cl.7 識別記号 FI A61P 9/00 A61P 9/00 17/14 17/14 25/32 25/32 43/00 43/00 (58)調査した分野(Int.Cl.7,DB名) A61K 31/198 A61K 31/401 A61K 31/405 A61K 31/70 A61K 47/26 A61P 9/00 A61P 17/14 A61P 25/32 A61P 43/00 CA(STN) MEDLINE(STN)Continued on the front page (51) Int.Cl. 7 Identification symbol FI A61P 9/00 A61P 9/00 17/14 17/14 25/32 25/32 43/00 43/00 (58) Fields surveyed (Int. Cl. 7 , DB name) A61K 31/198 A61K 31/401 A61K 31/405 A61K 31/70 A61K 47/26 A61P 9/00 A61P 17/14 A61P 25/32 A61P 43/00 CA (STN) MEDLINE (STN )
Claims (5)
れ以上の濃厚な糖:メソエリトリトール、キシリトー
ル、D(+)ガラクトース、D(+)ラクトース、D
(+)キシロース、ズルシット、ミオイノシトール、L
(−)フルクトース、D(−)マンニトール、ソルビト
ール、D(+)グルコース、D(+)アラビノース、D
(−)アラビノース、セロビオース、D(+)マルトー
ス、D(+)ラフィノース、L(+)ラムノース、D
(+)メリビオース、D(−)リボース、アドニット、
D(+)アラビトール、L(−)アラビトール、D
(+)フコース、L(−)フコース、D(−)リキソー
ス、L(+)リキソース、L(−)リキソース、D
(+)グルコサミン、Dマンノサミン及びDガラクトサ
ミン;及び (2)下記からなる群より選ぶいずれか一種又はそれ以
上のアミノ酸;グルタミン、リシン、アルギニン、アス
パラギン、アスパラギン酸、システイン、グルタミン
酸、グリシン、ヒスチジン、ロイシン、メチオニン、フ
ェニルアラニン、プロリン、セリン、トレオニン、トリ
プトファン、チロシン、バリン及びタウリン を含む物質を経口摂取することによって血液脳関門を通
過させるための組成物。(1) One or more concentrated sugars selected from the group consisting of: mesoerythritol, xylitol, D (+) galactose, D (+) lactose, D
(+) Xylose, dursit, myo-inositol, L
(-) Fructose, D (-) mannitol, sorbitol, D (+) glucose, D (+) arabinose, D
(-) Arabinose, cellobiose, D (+) maltose, D (+) raffinose, L (+) rhamnose, D
(+) Melibiose, D (-) ribose, adnit,
D (+) arabitol, L (-) arabitol, D
(+) Fucose, L (-) fucose, D (-) lyxose, L (+) lyxose, L (-) lyxose, D
(+) Glucosamine, D-mannosamine and D-galactosamine; and (2) one or more amino acids selected from the group consisting of: glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine A composition for crossing the blood-brain barrier by ingesting a substance containing methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine and taurine.
囲で、かつアミノ酸を典型的には400〜480ミリグラムの
範囲で含み、糖及びアミノ酸の最少量は患者の体重の変
化に応じる、酩酊を克服するために使用される特許請求
の範囲第1項記載の組成物。2. The composition of claim 1, further comprising sugar, typically in the range of 1.2-2.5 grams, and amino acids, typically in the range of 400-480 milligrams, wherein the minimum amounts of sugar and amino acids are associated with changes in patient weight. A composition according to claim 1 for use in overcoming drunkenness.
の内の少なくとも一種を含む毛髪の損失を遅らせるため
に使用される特許請求の範囲第1項記載の組成物。3. The composition according to claim 1, which is further used for delaying hair loss, comprising at least one of beta-carotene and xanthophyll.
することから時間を隔てた点で、典型的には毎日の量50
00IUで摂取することができる特許請求の範囲第3項記載
の組成物。4. The method according to claim 1, wherein said beta-carotene is administered in a daily dose, at a point spaced from ingestion of said composition.
4. The composition according to claim 3, which can be taken in 00IU.
て輸送するための手段となり、それらの組合せが脳内の
神経伝達物質の機能を向上させる特許請求の範囲第1項
記載の組成物。5. The composition according to claim 1, wherein the sugar component serves as a means for transporting the amino acid component through the blood-brain barrier, and a combination thereof enhances the function of a neurotransmitter in the brain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1186086A JP3051413B2 (en) | 1989-07-20 | 1989-07-20 | Substances that cross the blood-brain barrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1186086A JP3051413B2 (en) | 1989-07-20 | 1989-07-20 | Substances that cross the blood-brain barrier |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0352810A JPH0352810A (en) | 1991-03-07 |
| JP3051413B2 true JP3051413B2 (en) | 2000-06-12 |
Family
ID=16182129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1186086A Expired - Lifetime JP3051413B2 (en) | 1989-07-20 | 1989-07-20 | Substances that cross the blood-brain barrier |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3051413B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049012A3 (en) * | 2003-11-13 | 2005-07-21 | Shs Int Ltd | Tryptophan for use in promoting and maintaining abstinence |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294520B1 (en) * | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| GB9215768D0 (en) * | 1992-07-24 | 1992-09-09 | Agricultural & Food Res | Repression of virulent gene expression |
| US6929807B1 (en) | 1996-08-09 | 2005-08-16 | Mannatech, Inc. | Compositions of plant carbohydrates as dietary supplements |
| WO2002003848A2 (en) * | 2000-07-10 | 2002-01-17 | Naito Albert T | Method for opening the blood-brain barrier |
| JP2003327528A (en) * | 2002-03-04 | 2003-11-19 | Pharmafoods Kenkyusho:Kk | Immunocompetence-improving composition |
| DE602005025313D1 (en) * | 2004-02-17 | 2011-01-27 | Matuschka Greiffenclau Markus | COMPOSITION FOR CHANGING ALCOHOL TOOL CHANGES |
| DK1909600T3 (en) | 2005-07-29 | 2012-07-30 | Tima Foundation | Composition for moderation of alcohol metabolism and to reduce the risk of alcohol-caused diseases |
| FR2939029B1 (en) * | 2008-12-02 | 2011-03-04 | Oreal | ASSOCIATION OF REDUCED GLUTATHION, GLUTAMINE, LEUCINE, ASPARAGINE AND TYROSINE TO FIGHT ALOPECIA IN WOMEN |
| WO2010064203A1 (en) * | 2008-12-02 | 2010-06-10 | L'oreal | Combination of reduced glutathione and amino acids for improving the quality of the hair in women |
| FR2939038B1 (en) * | 2008-12-02 | 2011-02-25 | Oreal | ASSOCIATION OF GLUTAMIC ACID, THREONINE, ASPARAGINE AND ALANINE TO FIGHT ALOPECIA IN MAN |
| JP7313854B2 (en) * | 2019-03-25 | 2023-07-25 | キリンホールディングス株式会社 | Composition for improving the appearance of hair |
-
1989
- 1989-07-20 JP JP1186086A patent/JP3051413B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049012A3 (en) * | 2003-11-13 | 2005-07-21 | Shs Int Ltd | Tryptophan for use in promoting and maintaining abstinence |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0352810A (en) | 1991-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6294520B1 (en) | Material for passage through the blood-brain barrier | |
| JP3051413B2 (en) | Substances that cross the blood-brain barrier | |
| Sneddon | Adverse effect of topical fluorinated corticosteroids in rosacea | |
| Dubner et al. | Factors controlling brain potentials in the cat | |
| Mezey | Duration of the enhanced activity of the microsomal ethanol-oxidizing enzyme system and rate of ethanol degradation in ethanol-fed rats after withdrawal | |
| DE69131352T2 (en) | INCREASE IN GLUTATHION LEVEL THROUGH GLUTAMINE | |
| JP2830955B2 (en) | Uridine for use in pharmacological treatment of peripheral complications of diabetes | |
| JPH05339148A (en) | Substance penetrating blood-brain barrier | |
| EP0336960A4 (en) | Detoxifying food supplement. | |
| JPH04243825A (en) | Remedy for pigmentation | |
| EP0234186B1 (en) | Use of oligopeptids for the treatment of cerebral disorders | |
| Locket et al. | Methonium compounds in the treatment of hypertension | |
| JP3182564B2 (en) | Nutrition composition | |
| EP0366156B1 (en) | Composition for the treatment of diseases of the veins and the anal region | |
| Coskey et al. | Insulinoma and multiple neurofibromatosis: report of a case | |
| CA2162877C (en) | Monohydrate dextrose or glucose composition | |
| Silberstein et al. | Induction of adrenal tyrosine hydroxylase in organ culture | |
| RU2146529C1 (en) | Kit of antialcoholic agents | |
| US20050176829A1 (en) | Methods for treating hypothyroidism | |
| JP2557241B2 (en) | Anti-pigmenting agent | |
| JP2005002041A (en) | Water-soluble pearl powder | |
| Weil et al. | Effect of growth hormone on pyruvic acid metabolism | |
| CN117377454A (en) | Skin application composition for skin care | |
| KR20120119686A (en) | A functional beverage composition comprising l-arginine, vitamin c, vitamin b complex, vitamin a, vitamin e and potassium iodide as main ingredients | |
| US3168440A (en) | Stable vitamin composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090331 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100331 Year of fee payment: 10 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100331 Year of fee payment: 10 |